Please use this identifier to cite or link to this item:
Title: Micelle carriers based on dendritic macromolecules containing bis-MPA and glycine for antimalarial drug delivery
Author: Martí Coma-Cros, Elisabet
Lancelot, Alexandre
San Anselmo, María
Borgheti Cardoso, Livia Neves
Valle Delgado, Juan José
Serrano, José Luis
Fernàndez Busquets, Xavier
Sierra, Teresa
Keywords: Materials biomèdics
Vacuna de la malària
Biomedical materials
Malaria vaccine
Issue Date: 4-Feb-2019
Publisher: Royal Society of Chemistry
Abstract: Biomaterials for antimalarial drug transport still need to be investigated in order to attain nanocarriers that can tackle essential issues related to malaria treatment, e.g. complying with size requirements and targeting specificity for their entry into Plasmodium-infected red blood cells (pRBCs), and limiting premature drug elimination or drug resistance evolution. Two types of dendritic macromolecule that can form vehicles suitable for antimalarial drug transport are herein explored. A new hybrid dendritic-linear-dendritic block copolymer based on Pluronic\xC2\xAE F127 and amino terminated 2,2'-bis(glycyloxymethyl)propionic acid dendrons with a poly(ester amide) skeleton (HDLDBC-bGMPA) and an amino terminated dendronized hyperbranched polymer with a polyester skeleton derived from 2,2'-bis(hydroxymethyl)propionic acid (DHP-bMPA) have provided self-assembled and unimolecular micelles. Both types of micelle carrier are biocompatible and exhibit appropriate sizes to enter into pRBCs. Targeting studies have revealed different behaviors for each nanocarrier that may open new perspectives for antimalarial therapeutic approaches. Whereas DHP-bMPA exhibits a clear targeting specificity for pRBCs, HDLDBC-bGMPA is incorporated by all erythrocytes. It has also been observed that DHP-bMPA and HDLDBC-bGMPA incorporate into human umbilical vein endothelial cells with different subcellular localization, i.e. cytosolic and nuclear, respectively. Drug loading capacity and encapsulation efficiencies for the antimalarial compounds chloroquine, primaquine and quinacrine ranging from 30% to 60% have been determined for both carriers. The resulting drug-loaded nanocarriers have been tested for their capacity to inhibit Plasmodium growth in in vitro and in vivo assays.
Note: Reproducció del document publicat a:
It is part of: Biomaterials science, 2019, vol. 7, num. 4, p. 1661-1674
Related resource:
ISSN: 2047-4830
Appears in Collections:Articles publicats en revistes (ISGlobal)
Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))
Articles publicats en revistes (Institut de Nanociència i Nanotecnologia (IN2UB))

Files in This Item:
File Description SizeFormat 
Mart_Coma-CrosE_Biomater_Sci_2019.pdf4.97 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons